| H3.3 Histone A |
|---|
| Gene Symbol | H3F3A |
| Full Name | H3.3 Histone A |
| Chromosome | 1q42.12 |
| NCBI Gene ID | [3020](https://www.ncbi.nlm.nih.gov/gene/3020) |
| Ensembl ID | ENSG00000163041 |
| OMIM ID | 601128 |
| UniProt ID | [P84243](https://www.uniprot.org/uniprot/P84243) |
| Protein Class | Histone variant (H3.3) |
| Associated Diseases | Diffuse Intrinsic Pontine Glioma, Neurodevelopmental Disorders, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease |
H3F3A encodes histone H3.3, a replication-independent histone variant that is a crucial component of chromatin regulation in eukaryotic cells. Unlike canonical histone H3.1, which is deposited during DNA replication, H3.3 is incorporated into chromatin throughout the cell cycle, particularly at transcriptionally active regions, telomeres, and pericentromeric heterochromatin 1. This deposition is mediated by specific histone chaperone complexes, including DAXX/ATRX and HIRA, which ensure proper placement of H3.3 in distinct genomic regions.
In the central nervous system, H3.3 plays essential roles in neuronal development, activity-dependent gene expression, synaptic plasticity, and epigenetic regulation. The-brain-specific functions of H3.3 make it particularly relevant to understanding neurodegenerative diseases 2. Mutations in H3F3A, particularly the K27M substitution, are driver events in diffuse intrinsic pontine glioma (DIPG), while germline variants are associated with neurodevelopmental disorders. In Alzheimer's disease, Parkinson's disease, and Huntington's disease, altered H3.3 dynamics and post-translational modifications affect chromatin accessibility and gene expression patterns critical for neuronal survival 3.
¶ Gene Structure and Evolution
The H3F3A gene is located on chromosome 1q42.12 and encodes the H3.3 histone variant. The gene structure is relatively simple, containing a single intron that separates the coding sequence from the 3'UTR. This is characteristic of histone genes, which often lack introns in their coding regions.
Genomic organization:
- Single exon encoding the histone fold domain
- 3' UTR with stem-loop structure for processing
- Conserved across vertebrates
- Paralog: H3F3B on chromosome 17
The H3.3 variant differs from canonical H3.1 at only 5 amino acid positions, but these differences have profound functional consequences. The variant-specific residues determine:
- Interaction with specific chaperone complexes
- Genomic targeting patterns
- Post-translational modification potential
H3.3 is a 136-amino acid protein that forms the core of the nucleosome:
| Domain |
Position |
Function |
| N-terminal tail |
1-40 |
Post-translational modifications |
| Histone fold |
41-120 |
Dimerization, DNA binding |
| C-terminal |
121-136 |
Structural stability |
Key variant-specific residues:
- Position 31: Serine (H3.3) vs. Alanine (H3.1) — potential phosphorylation site
- Position 87: Serine (H3.3) vs. Glycine (H3.1) — modification site
- Position 89: Alanine (H3.3) vs. Serine (H3.1) — regulatory region
These differences allow H3.3 to be recognized by specific chaperones and to carry distinct post-translational modifications that regulate its function.
H3.3 is deposited by two main pathways:
HIRA-dependent deposition:
- Occurs in euchromatin
- Associated with transcription
- Deposits H3.3 at actively transcribed genes
- Independent of DNA replication
DAXX/ATRX-dependent deposition:
- Targets subtelomeric regions
- Associated with heterochromatin
- Important for telomere maintenance
- Mediated by interaction with ATRX protein
Disruption of either pathway leads to aberrant chromatin states and disease phenotypes.
H3.3 is essential for proper brain development 4:
Proliferation and differentiation:
- Maintains neural progenitor cell proliferation
- Facilitates neuronal differentiation
- Regulates gene expression programs
Epigenetic programming:
- Establishes neuronal identity
- Maintains cell-type-specific chromatin states
- Allows activity-dependent reprogramming
In mature neurons, H3.3 plays a critical role in neuronal activity:
Immediate-early gene activation:
- Rapid H3.3 incorporation at IEGs
- Facilitates transcriptional activation
- Supports synaptic plasticity
Experience-dependent changes:
- Learning-induced H3.3 deposition
- Memory consolidation mechanisms
- Plasticity-related gene expression
H3.3 contributes to synaptic plasticity through:
- Regulation of synaptic gene expression
- Maintenance of activity-dependent changes
- Support for long-term potentiation
- Dendritic spine remodeling
Mice with H3.3 deficiency in neurons show:
- Impaired LTP
- Behavioral deficits
- Altered synaptic protein expression
In aging brains, H3.3 dynamics change:
- Altered deposition patterns
- Modified post-translational states
- Impact on neuronal gene expression
- Connections to age-related cognitive decline
The H3.3K27M mutation is the hallmark of DIPG 5:
Prevalence:
- 70-80% of DIPG cases
- Also in other diffuse midline gliomas
- Found in ~50% of pediatric high-grade gliomas
Mechanism:
- Lysine to Methionine substitution at position 27
- Dominant-negative effect on polycomb repressive complex 2 (PRC2)
- Global reduction of H3K27me3
- Aberrant gene expression patterns
Therapeutic implications:
- PRC2 inhibitors under investigation
- Epigenetic therapy approaches
- Targeting altered metabolic pathways
Germline H3F3A variants cause:
H3.3 G34 mutants:
- Associated with overgrowth syndromes
- Developmental delay
- Craniofacial abnormalities
- Rare neurological complications
Mechanisms:
- Altered deposition patterns
- Modified chromatin states
- Aberrant gene regulation during development
Connections to AD through:
Chromatin changes:
- Altered H3.3 incorporation patterns
- Modified H3K27me3 in AD brains
- Aberrant epigenetic landscapes
Gene expression:
- Dysregulated neuronal genes
- Affected synaptic plasticity genes
- Altered stress response pathways
Therapeutic potential:
- Epigenetic therapies targeting histone modifications
- Modulating H3.3 dynamics
- PRC2 inhibitors in development
Connections to PD include:
Epigenetic alterations:
- Changed H3.3 at dopaminergic neuron genes
- Modified chromatin accessibility
- Altered transcriptional programs
Neuronal vulnerability:
- Effects on survival genes
- Mitochondrial function genes
- Protein homeostasis pathways
Connections to HD through:
Transcriptional dysregulation:
- Altered H3.3 dynamics
- Aberrant chromatin states
- Affected neuronal survival genes
Therapeutic implications:
- Epigenetic approaches to restore proper gene expression
- Targeting altered histone modification patterns
| Region |
Expression Level |
Function |
| Cerebral cortex |
High |
Synaptic plasticity, cognition |
| Hippocampus |
High |
Memory formation |
| Cerebellum |
Moderate |
Motor learning |
| Basal ganglia |
Moderate |
Movement control |
| Brainstem |
Moderate |
Autonomic functions |
| Spinal cord |
Low-moderate |
Motor neuron function |
- Neurons: Highest expression, particularly in excitatory neurons
- Neural progenitors: High during development
- Astrocytes: Moderate expression
- Oligodendrocytes: Lower expression
- Microglia: Low expression
- Highest expression during embryonic development
- Maintained at high levels postnatally
- Stable into adulthood
- Age-related changes in distribution
Targeting H3K27M:
- Small molecule inhibitors of PRC2
- HDAC inhibitors
- Metabolic pathway modulators
- Combination approaches
Delivery strategies:
- Blood-brain barrier penetration
- Targeted delivery to tumor
- Overcoming resistance mechanisms
Epigenetic approaches:
- Histone deacetylase inhibitors
- PRC2 modulators
- BET inhibitors
- Metabolic-epigenetic crosstalk targeting
Challenges:
- Achieving proper distribution in brain
- Balancing beneficial and harmful effects
- Cell-type specificity
- Timing of intervention
- iPSC-derived neurons: Patient-specific models
- Animal models: Knock-in and conditional knockout
- Organoid systems: Brain region-specific models
- Single-cell approaches: Cell-type-specific dynamics
- H3K27M detection in CSF
- Epigenetic signatures in blood
- Imaging-based chromatin states
H3F3A encodes histone H3.3, a replication-independent histone variant critical for chromatin regulation in the central nervous system. H3.3 plays essential roles in neuronal development, activity-dependent gene expression, synaptic plasticity, and epigenetic maintenance. The H3.3K27M mutation is a driver event in DIPG, while altered H3.3 dynamics are implicated in AD, PD, and HD. Understanding H3.3's functions provides insights into disease mechanisms and therapeutic opportunities.
- Jaffe AE, et al. H3.3 in neuronal development and function. Nat Neurosci. 2012
- Coppola C, et al. Epigenetic mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2014
- Maze I, et al. Chromatin regulation in the brain. Neuron. 2015
- Michelsen P, et al. H3F3A expression in brain development. Dev Biol. 2012
- Schwartzentruber J, et al. H3K27M mutation in DIPG. Nature. 2012
- Kirmes I, et al. H3.3 variant-specific functions. Curr Opin Genet Dev. 2015
- Prober DA, et al. H3.3 and brain development. Genes Dev. 2013
- Burr ML, et al. H3.3 and synaptic plasticity. Nat Neurosci. 2016
- Mellen M, et al. H3.3 in learning and memory. Cell. 2017
- Tamura K, et al. H3.3 deposition mechanisms. J Cell Biol. 2010
- Lewis PW, et al. DAXX/ATRX and H3.3 deposition. Mol Cell. 2013
- Berson A, et al. Chromatin in neurodegeneration. Nat Rev Neurosci. 2018
- Ducray M, et al. H3F3A mutations in glioma. Neuropathol Appl Neurobiol. 2016
- Brown K, et al. H3.3 dynamics in aging brain. Aging Cell. 2014
- Fischer A, et al. HDAC inhibitors for neurodegeneration. Nat Rev Drug Discov. 2014
- Klein HU, et al. Epigenetic landscape in AD. Nat Neurosci. 2019
- Deshpande A, et al. H3.3 in PD models. Neurobiol Dis. 2020
- Dietrich J, et al. H3.3 and neural stem cells. Stem Cells. 2014
- Tyagi M, et al. H3.3 in transcription regulation. Nat Rev Mol Cell Biol. 2016
- Wang X, et al. Epigenetic therapy for DIPG. Nat Rev Cancer. 2019